Core Viewpoint - The domestic nine-valent HPV vaccine is gaining popularity among women in China, with increasing consultation and vaccination rates as it becomes more accessible through community health service centers [1][3][4]. Group 1: Rising Vaccination Rates - In cities like Zhengzhou, Xiamen, and Guangzhou, there is a noticeable increase in the number of people waiting for vaccination and inquiring about the vaccination process [3]. - The domestic nine-valent vaccine accounts for over 60% of the total HPV vaccinations at some community health service centers, indicating a significant shift in preference [3][4]. - Feedback from various vaccination points shows that the domestic nine-valent vaccine is becoming the preferred choice among women, with many no longer hesitating to choose it over imported options [4][6]. Group 2: Factors Driving Preference - Key factors contributing to the rapid acceptance of the domestic nine-valent HPV vaccine include safety, effectiveness, affordability, and technological maturity [6][9]. - The use of an E. coli expression system in the vaccine makes it more relatable and acceptable to the public, enhancing trust in its safety [8]. - Clinical trial data indicates that the immunogenicity of the domestic nine-valent vaccine is comparable to that of imported vaccines, further boosting confidence among healthcare providers and recipients [9]. Group 3: Positive User Experience - Many vaccine recipients report a smooth and clear vaccination process, leading to a positive overall experience [11]. - Mild and quickly resolving side effects have shifted perceptions from worry to reassurance among recipients, contributing to a growing willingness to get vaccinated [12]. - Positive experiences are driving word-of-mouth recommendations, with individuals encouraging friends and colleagues to get vaccinated after their own experiences [13]. Group 4: Future Outlook - The increasing consultation and vaccination rates, along with the accumulation of positive feedback, suggest a promising future for the domestic nine-valent HPV vaccine as it becomes more accessible and trusted among women [13].